Showing results (81-90 of 239) with videos related to

Sort By:
Pageof 24
The Journal of Pathology|June 25, 2013
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancersAntje Krohn, Annemarie Seidel, Lia Burkhardt, et al.
The Prostate|January 15, 2016
Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancerNathaniel Melling, Berivan Taskin, Claudia Hube-Magg, et al.
Plos One|August 1, 2015
High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate CancerNathaniel Melling, Levon Harutyunyan, Claudia Hube-Magg, et al.
Endocrine Pathology|March 8, 2020
Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine CarcinomasChristoph Fraune, Ronald Simon, Claudia Hube-Magg, et al.
Oncology Reports|July 3, 2015
Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletionKatharina Grupp, Laura Roettger, Martina Kluth, et al.
Oncotarget|August 22, 2015
Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancerMartina Kluth, Ramin Ahrary, Claudia Hube-Magg, et al.
Cancer Biology & Medicine|February 25, 2021
Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancerAndreas Marx, Lena Koopmann, Doris Höflmayer, et al.
Oncotarget|November 19, 2016
Deletion of 18q is a strong and independent prognostic feature in prostate cancerMartina Kluth, Maximilian Graunke, Christina Möller-Koop, et al.
Experimental and Molecular Pathology|March 22, 2015
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancerChristoph Burdelski, Oliver M Ruge, Nathaniel Melling, et al.
Genes, Chromosomes & Cancer|January 10, 2019
5q21 deletion is often heterogeneous in prostate cancerMartina Kluth, Zaid Al Kilani, Cansu Özden, et al.
Pageof 24